

# Yvonne Y Li

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12190731/publications.pdf>

Version: 2024-02-01

28  
papers

3,049  
citations

361413

20  
h-index

526287

27  
g-index

28  
all docs

28  
docs citations

28  
times ranked

6226  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. <i>Journal of Thoracic Oncology</i> , 2022, 17, 399-410.	1.1	151
2	Sex-Biased <i>ZRSR2</i> Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis. <i>Cancer Discovery</i> , 2022, 12, 522-541.	9.4	44
3	Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. <i>JAMA Oncology</i> , 2022, 8, 1160.	7.1	117
4	Quantification of aneuploidy in targeted sequencing data using ASCETS. <i>Bioinformatics</i> , 2021, 37, 2461-2463.	4.1	21
5	Genomic Characterization of <i>de novo</i> Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1105-1118.	7.0	24
6	Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. <i>Clinical Cancer Research</i> , 2021, 27, 1695-1705.	7.0	19
7	SMARCA4 and Other SWItch/Sucose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1176-1187.	1.1	49
8	Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. <i>Cell</i> , 2021, 184, 6119-6137.e26.	28.9	201
9	Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q. <i>Cell Reports</i> , 2020, 33, 108493.	6.4	28
10	Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4135-4142.	7.0	95
11	Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC. <i>Clinical Cancer Research</i> , 2020, 26, 2615-2625.	7.0	129
12	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. <i>Cancer Immunology Research</i> , 2020, 8, 1075-1084.	3.4	47
13	Mechanisms and therapeutic implications of hypermutation in gliomas. <i>Nature</i> , 2020, 580, 517-523.	27.8	374
14	Near haploidization is a genomic hallmark which defines a molecular subgroup of giant cell glioblastoma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa155.	0.7	4
15	Male-Biased Spliceosome Mutations in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Impair pDC Activation and Apoptosis. <i>Blood</i> , 2020, 136, 13-14.	1.4	1
16	Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer. <i>Molecular Cancer Research</i> , 2019, 17, 2281-2293.	3.4	29
17	Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity. , 2019, 7, 32.		92
18	Exome and genome sequencing of nasopharynx cancer identifies NF- $\kappa$ B pathway activating mutations. <i>Nature Communications</i> , 2017, 8, 14121.	12.8	227

#	ARTICLE	IF	CITATIONS
19	Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. JCI Insight, 2016, 1, e87415.	5.0	125
20	Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer. Cancer Discovery, 2016, 6, 1006-1021.	9.4	108
21	Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2016, 22, 2939-2949.	7.0	51
22	STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Research, 2016, 76, 999-1008.	0.9	451
23	Analysis of immune infiltrates in a genomically characterized clinical cohort of head and neck squamous cell carcinoma (HNSCC) patients (pts).. Journal of Clinical Oncology, 2016, 34, 6052-6052.	1.6	1
24	Genomic Analysis of Metastatic Cutaneous Squamous Cell Carcinoma. Clinical Cancer Research, 2015, 21, 1447-1456.	7.0	235
25	Genomic Landscape of Human Papillomavirus-Associated Cancers. Clinical Cancer Research, 2015, 21, 2009-2019.	7.0	104
26	NSCLC Driven by <i>DDR2</i> Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy. Molecular Cancer Therapeutics, 2015, 14, 2382-2389.	4.1	29
27	Drug repositioning for personalized medicine. Genome Medicine, 2012, 4, 27.	8.2	186
28	A Computational Approach to Finding Novel Targets for Existing Drugs. PLoS Computational Biology, 2011, 7, e1002139.	3.2	107